Press releases
-
-
-
-
-
-
Internal link ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
-
-
-
-
-
-
Internal link ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
-
-
Internal link ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
-
-
-
Internal link ProQR Announces Planned Changes to Board Composition
-
Internal link ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
-
Internal link ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital
-
Internal link ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
-
Internal link ProQR Announces Highlights from Analyst Event
-
Internal link ProQR to Webcast Virtual Analyst Event on November 18
-
-
-